	US 11,891,400 B2
	Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
Zhaogen Chen, Carmel, IN (US); Jon Andre Erickson, Carmel, IN (US); and Gaiying Zhao, Carmel, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Appl. No. 17/268,644
Filed by Eli Lilly and Company, Indianapolis, IN (US)
PCT Filed Sep. 4, 2019, PCT No. PCT/US2019/049448 § 371(c)(1), (2) Date Feb. 16, 2021, PCT Pub. No. WO2020/055636, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/728,913, filed on Sep. 10, 2018.
Prior Publication US 2021/0188861 A1, Jun. 24, 2021
Int. Cl. C07D 487/04 (2006.01); C07D 487/02 (2006.01); A61P 17/06 (2006.01); A61P 37/00 (2006.01)

CPC C07D 487/04 (2013.01) [A61P 17/06 (2018.01); A61P 37/00 (2018.01); C07D 487/02 (2013.01)]

11 Claims

1. A compound of the formula:

OG Complex Work Unit Chemistry

wherein R is methyl or ethyl;

or a pharmaceutically acceptable salt thereof.